

Giuseppe Badalamenti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3582509/publications.pdf>

Version: 2024-02-01

69
papers

1,312
citations

411340

20
h-index

425179

34
g-index

71
all docs

71
docs citations

71
times ranked

2181
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	3.2	18
2	Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective caseâ€series analysis from the Italian Rare Cancers Network. <i>Cancer</i> , 2022, 128, 1439-1448.	2.0	5
3	Deep Learning Networks for Automatic Retroperitoneal Sarcoma Segmentation in Computerized Tomography. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 1665.	1.3	11
4	Safety and effectiveness of gemcitabine for the treatment of classic Kaposiâ€™s sarcoma without visceral involvement. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210868.	1.4	0
5	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	0.8	15
6	Heart toxicity effects (HTE) of anthracyclines-containing regimens (ACRs) in patients with breast cancer (BC) carrying mutational signature of homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2022, 40, 10519-10519.	0.8	0
7	Immunometabolic predictive factors in Merkel cell carcinoma (MCC) patients treated with avelumab.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21525-e21525.	0.8	2
8	Not all <i>KIT</i> 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110497.	1.4	3
9	Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon. <i>Cancers</i> , 2021, 13, 993.	1.7	14
10	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. <i>Cancers</i> , 2021, 13, 1053.	1.7	15
11	Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?. <i>Cancers</i> , 2021, 13, 2118.	1.7	23
12	Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors. <i>European Radiology</i> , 2021, 31, 8554-8564.	2.3	20
13	Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors (GIST): A retrospective, multicenter, real-world study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e23521-e23521.	0.8	0
14	Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome. <i>Frontiers in Oncology</i> , 2021, 11, 682445.	1.3	14
15	Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103390.	2.0	10
16	Gastrointestinal Stromal Tumors (GISTs). <i>UNIPA Springer Series</i> , 2021, , 1021-1059.	0.1	0
17	Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 78-84.	1.8	39
18	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 194-200.	1.8	32

#	ARTICLE	IF	CITATIONS
19	Duodenal perforation as presentation of gastric neuroendocrine tumour: A case report. <i>International Journal of Surgery Case Reports</i> , 2020, 77, S105-S108.	0.2	1
20	A Lymphocyte MicroRNA Signature as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming. <i>Cancers</i> , 2020, 12, 3396.	1.7	41
21	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. <i>Oncolmmunology</i> , 2020, 9, 1832348.	2.1	55
22	Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2. <i>Cancers</i> , 2020, 12, 2415.	1.7	40
23	Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1351.	1.0	5
24	Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily) – Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes. <i>Cancers</i> , 2020, 12, 1158.	1.7	30
25	Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience. <i>Oncology</i> , 2020, 98, 445-451.	0.9	26
26	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. <i>Cancers</i> , 2020, 12, 740.	1.7	28
27	<i>BRCA1/2</i> pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097532.	1.4	34
28	Fatal Heart Failure Induced By Pazopanib In A Sarcoma Patient Previously Treated With Gemcitabine. <i>Journal of the Saudi Heart Association</i> , 2020, 32, 285-287.	0.2	2
29	How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 68-75.	2.0	4
30	How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1189.	1.7	4
31	Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). <i>Advances in Therapy</i> , 2019, 36, 2600-2617.	1.3	80
32	Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987465.	1.4	27
33	Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984887.	1.4	30
34	Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. <i>Cancers</i> , 2019, 11, 749.	1.7	4
35	Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes. <i>Cancer Epidemiology</i> , 2019, 59, 258-264.	0.8	18
36	Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. <i>Endocrine</i> , 2019, 66, 417-424.	1.1	25

#	ARTICLE	IF	CITATIONS
37	Dedifferentiated retroperitoneal large liposarcoma and laparoscopic treatment: Is it possible and safe? The first literature case report. <i>International Journal of Surgery Case Reports</i> , 2019, 57, 113-117.	0.2	14
38	One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients. <i>Supportive Care in Cancer</i> , 2019, 27, 3593-3597.	1.0	10
39	Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	13
40	Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?. <i>Cellular Immunology</i> , 2019, 343, 103753.	1.4	187
41	Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives. <i>Radiologia Medica</i> , 2019, 124, 259-265.	4.7	10
42	Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. <i>European Journal of Endocrinology</i> , 2019, 181, 681-689.	1.9	30
43	Advanced epithelioid haemangioendotelioma: Fever, pain, and pleural effusion predict a worse outcome.. <i>Journal of Clinical Oncology</i> , 2019, 37, e22540-e22540.	0.8	0
44	Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11032-11032.	0.8	0
45	A novel predictive biomarker of immunotherapy response in metastatic renal cell carcinoma (mRCC): The lymphocyte microRNA expression profile.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16109-e16109.	0.8	0
46	Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. <i>Oncology</i> , 2018, 95, 1-7.	0.9	7
47	The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2018, 8, 13379.	1.6	66
48	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879462.	1.4	27
49	Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. <i>International Journal of Cardiology</i> , 2017, 227, 11-17.	0.8	64
50	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 731-739.	1.4	20
51	Liquid Biopsy in Gastrointestinal Stromal Tumor. <i>Current Clinical Pathology</i> , 2017, , 151-159.	0.0	1
52	Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11038-11038.	0.8	0
53	Doxorubicin plus dacarbazine (DTIC) in advanced solitary fibrous tumor (SFT): An Italian retrospective case series analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11042-11042.	0.8	2
54	Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. <i>Oncotarget</i> , 2016, 7, 69412-69419.	0.8	17

#	ARTICLE	IF	CITATIONS
55	Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 21259-21271.	0.8	16
56	Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in angiosarcoma and leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11062-11062.	0.8	0
57	A single-Institution retrospective analysis of metastatic bronchial carcinoids with a focus on recurrence pattern.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20586-e20586.	0.8	0
58	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 10.	3.5	65
59	Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10515-10515.	0.8	1
60	Treatment and outcome(s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15568-e15568.	0.8	0
61	A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15588-e15588.	0.8	0
62	Trabectedin-related liver toxicity in soft tissue sarcoma patients: Always a good reason to discontinue the treatment?. <i>Journal of Clinical Oncology</i> , 2014, 32, 10572-10572.	0.8	0
63	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e83026.	1.1	66
64	Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10551-10551.	0.8	1
65	Natural history of malignant bone disease in non-small cell lung cancer: Preliminary results of a multicenter bone metastasis survey.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19084-e19084.	0.8	1
66	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA10008-LBA10008.	0.8	2
67	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA10008-LBA10008.	0.8	11
68	Bone metastases in soft tissue sarcoma patients: A survey of natural, prognostic value, and treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10063-10063.	0.8	0
69	A Case of Squamocellular Uterine Cervix Carcinoma Metastatic to the Skin with Enterocutaneous Fistula. <i>Tumori</i> , 2006, 92, 264-266.	0.6	0